Literature DB >> 8558460

YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.

M Shimizu-Sasamata1, S Kawasaki-Yatsugi, M Okada, S Sakamoto, S Yatsugi, J Togami, K Hatanaka, J Ohmori, K Koshiya, S Usuda, K Murase.   

Abstract

We investigated the pharmacological properties and neuroprotective actions of a novel alpha-amino-3-hydroxy-5-methylisoxazole-y-propionate (AMPA)/kainate receptor antagonist, [6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione hydrochloride (YM90K); formerly YM900], in comparison with those of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). YM90K selectively displaced [3H]-AMPA binding (Ki = 0.084 microM) and was less potent in inhibiting [3H]-kainate (Ki = 2.2 microM), [3H]-L-glutamate (N-methyl-D-aspartate-sensitive site; Ki > 100 microM) and [3H]-glycine (strychnine-insensitive site; Ki = 37 microM) binding to rat brain membranes. YM90K co-injected with AMPA or kainate into the rat striatum protected cholinergic neurons against AMPA- or kainate-induced neurotoxicity. YM90K showed potent suppressive activity against audiogenic seizure in DBA/2 mice; ED50 values of YM90K and NBQX against tonic seizure were 2.54 and 7.17 mg/kg (i.p.), respectively. The duration of the anticonvulsant effects of YM90K and NBQX was 30 min, indicating that both compounds possess short action. In a global ischemia model, YM90K (15 mg/kg i.p. x 3), NBQX (30 mg/kg i.p. x 3) and CNQX (60 mg/kg i.p. x 3) significantly prevented the delayed neuronal death in the hippocampal CA1 region in Mongolian gerbils when administered 1 h after 5-min ischemia. In addition, the therapeutic time window for the neuroprotective effect of YM90K (30 mg/kg i.p. x 3) was 6 h. In a focal ischemia model, YM90K (30 mg/kg i.v. bolus+10 mg/kg/h for 4 h) reduced the volume of ischemic damage in the cerebral cortex in F344 rats. Thus, YM90K was shown to be a potent and selective antagonist for AMPA/kainate receptors in vitro and in vivo. This compound may provide a therapeutic effect in various neurodegenerative disorders such as ischemic stroke in which glutamate neurotoxicity is thought to play a critical role in neuronal damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558460

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis.

Authors:  D D Mitsikostas; M Sanchez del Rio; C Waeber; Z Huang; F M Cutrer; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 2.  The regulation of AMPA receptor-binding sites.

Authors:  K K Dev; J M Henley
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

3.  Systemic Administration of the AMPA Receptor Antagonist, NBQX, Reduces Alcohol Drinking in Male C57BL/6J, But Not Female C57BL/6J or High-Alcohol-Preferring, Mice.

Authors:  Meredith R Bauer; Daniel P Garcy; Stephen L Boehm
Journal:  Alcohol Clin Exp Res       Date:  2020-10-03       Impact factor: 3.455

4.  Effects of AMPA receptor antagonist, NBQX, and extrasynaptic GABAA agonist, THIP, on social behavior of adolescent and adult rats.

Authors:  Carol A Dannenhoffer; Elena I Varlinskaya; Linda Patia Spear
Journal:  Physiol Behav       Date:  2018-05-22

Review 5.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

6.  Identification and characterization of RNA aptamers: A long aptamer blocks the AMPA receptor and a short aptamer blocks both AMPA and kainate receptors.

Authors:  William J Jaremko; Zhen Huang; Wei Wen; Andrew Wu; Nicholas Karl; Li Niu
Journal:  J Biol Chem       Date:  2017-03-21       Impact factor: 5.157

7.  ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.

Authors:  L Turski; A Huth; M Sheardown; F McDonald; R Neuhaus; H H Schneider; U Dirnagl; F Wiegand; P Jacobsen; E Ottow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 8.  AMPA receptors as a molecular target in epilepsy therapy.

Authors:  M A Rogawski
Journal:  Acta Neurol Scand Suppl       Date:  2013

Review 9.  Blockade of ion channels as an approach to studying AMPA receptor subtypes.

Authors:  L G Magazanik
Journal:  Neurosci Behav Physiol       Date:  2000 Jan-Feb

10.  AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role.

Authors:  Kuang-Ti Chen; Mang-Hung Tsai; Ching-Hsiang Wu; Ming-Jia Jou; I-Hua Wei; Chih-Chia Huang
Journal:  Front Behav Neurosci       Date:  2015-06-18       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.